Regenerative Patch Technologies

Portola Valley, United States· Est. 2011

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Regenerative Patch Technologies is a private, clinical-stage biotech focused on a novel implantable therapy for geographic atrophy, the advanced form of dry age-related macular degeneration (AMD). Its core technology, the CPCB-RPE1 implant, combines stem cell-derived RPE cells on a synthetic membrane to replace degenerated eye structures. The company has completed a Phase I/IIa trial with encouraging vision preservation/gain signals and is now enrolling patients in a Phase IIb trial, supported by significant non-dilutive funding from CIRM and foundations. RPT represents a potentially transformative, one-time surgical alternative to current chronic injection therapies that only slow disease progression.

OphthalmologyRetinal Diseases

Technology Platform

Bioengineered implant consisting of stem cell-derived retinal pigmented epithelial (RPE) cells cultured on an ultrathin synthetic parylene membrane for subretinal implantation.

Funding History

GrantUndisclosedCalifornia Institute for Regenerative MedicineJun 15, 2019

Opportunities

The lead program addresses a large, growing, and underserved market of patients with geographic atrophy, where current therapies only slow progression and require frequent injections.

A successful one-time implant that improves vision would represent a major therapeutic breakthrough and command a significant market share.

The cryopreserved formulation enhances commercial scalability.

Risk Factors

High clinical risk that the Phase IIb trial may not confirm earlier efficacy signals or may identify new safety concerns.

Surgical delivery carries inherent procedural risks.

Evolving competitive landscape with newly approved and pipeline drugs for GA.

Future significant capital required for Phase III and commercialization.

Competitive Landscape

Competition includes approved complement inhibitors (Syfovre, Izervay) which slow lesion growth but require chronic injections and do not improve vision. Other competitors are developing gene therapies, oral drugs, and cell-based approaches (e.g., Lineage Cell Therapeutics' OpRegen). RPT differentiates with its durable, surgically implanted patch designed to structurally replace damaged tissue and restore function.